```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN
 NEWS 20  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS 21  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'MEDLINE' ENTERED AT 18:21:55 ON 29 JAN 2004

FILE 'USPATFULL' ENTERED AT 18:21:55 ON 29 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s TIMP-1
L1         5340 TIMP-1

=> s cerebus protein
L2            1 CEREBUS PROTEIN

=> s brain derived neurotrophic factor or BDNF
L3        10853 BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF

=> s interferon alpha
L4        41802 INTERFERON ALPHA

=> s interferon beta
L5        14602 INTERFERON BETA

=> s albumin
L6       258098 ALBUMIN

=> s l6 and fusion
L7        30354 L6 AND FUSION

=> s l7 and l1
L8          214 L7 AND L1

=> s l7 and l2
L9            0 L7 AND L2

=> s l7 and l3
L10         636 L7 AND L3

=> s l7 and l4
L11        1550 L7 AND L4

=> s l7 and l5
L12        1361 L7 AND L5

=> s l6 and l2
L13           0 L6 AND L2

=> d l8 ti abs ibib 1-20
```

L8 ANSWER 1 OF 214 USPATFULL on STN

TI Molecules for diagnostics and therapeutics

AB The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.

ACCESSION NUMBER: 2004:18785 USPATFULL

TITLE: Molecules for diagnostics and therapeutics

INVENTOR(S): Hodgson, David M., Ann Arbor, MI, UNITED STATES
Lincoln, Stephen E., Potomac, MD, UNITED STATES
Russo, Frank D., Sunnyvale, CA, UNITED STATES
Albany, Peter A., Berkeley, CA, UNITED STATES
Banville, Steve C., Sunnyvale, CA, UNITED STATES
Bratcher, Shawn R., Mountain View, CA, UNITED STATES
Dufour, Gerard E., Castro Valley, CA, UNITED STATES
Cohen, Howard J., Palo Alto, CA, UNITED STATES
Rosen, Bruce H., Menlo Park, CA, UNITED STATES
Chalup, Michael S., Livingston, TX, UNITED STATES
Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES
Jones, Anissa L., San Jose, CA, UNITED STATES
Yu, Jimmy Y., Fremont, CA, UNITED STATES
Greenawalt, Lila B., San Jose, CA, UNITED STATES
Panzer, Scott R., Sunnyvale, CA, UNITED STATES
Roseberry Lincoln, Ann M., Potomac, MD, UNITED STATES
Wright, Rachel J., Merivale, NEW ZEALAND
Daniels, Susan E., Mountain View, CA, UNITED STATES

PATENT ASSIGNEE(S): Incyte Corporation, Palo Alto, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014087	A1	20040122
APPLICATION INFO.:	US 2003-378029	A1	20030228 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-980285, filed on 30 Nov 2001, PENDING A 371 of International Ser. No. WO 2000-US15404, filed on 31 May 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147500P	19990805 (60)
	US 1999-147542P	19990805 (60)
	US 1999-147541P	19990805 (60)
	US 1999-147824P	19990805 (60)
	US 1999-147547P	19990805 (60)
	US 1999-147530P	19990805 (60)
	US 1999-147536P	19990805 (60)
	US 1999-147520P	19990805 (60)
	US 1999-147527P	19990805 (60)
	US 1999-147549P	19990805 (60)
	US 1999-147377P	19990804 (60)
	US 1999-147436P	19990804 (60)
	US 1999-137411P	19990603 (60)
	US 1999-137396P	19990603 (60)
	US 1999-137417P	19990603 (60)
	US 1999-137337P	19990603 (60)
	US 1999-137173P	19990602 (60)

	US 1999-137114P	19990602 (60)
	US 1999-137259P	19990602 (60)
	US 1999-137113P	19990602 (60)
	US 1999-137260P	19990602 (60)
	US 1999-137258P	19990602 (60)
	US 1999-137109P	19990602 (60)
	US 1999-137161P	19990601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	14819	

L8 ANSWER 2 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:18737 USPATFULL	
TITLE:	Nucleic acids, proteins, and antibodies	
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES	
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)

US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)

US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 26776

L8 ANSWER 3 OF 214 USPATFULL on STN
TI **Albumin fusion** proteins
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER:	2004:13611 USPATFULL		
TITLE:	**Albumin fusion** proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-256931P		20001221 (60)
	US 2000-199384P		20000425 (60)
	US 2000-229358P		20000412 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	25066		

L8 ANSWER 4 OF 214 USPATFULL on STN
TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:13598 USPATFULL		
TITLE:	7 Human ovarian and ovarian cancer associated proteins		
INVENTOR(S):	Birse, Charles E., North Potomac, MD, UNITED STATES Rosen, Craig A., Laytonsville, MD, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115

APPLICATION INFO.: US 2003-333900 A1 20030124 (10)
WO 2001-US8585 20010316
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L8 ANSWER 5 OF 214 USPATFULL on STN
TI Use of bioactive glass compositions to stimulate osteoblast production
AB Compositions comprising bioactive glass compositions or extracts thereof which include ions in an appropriate concentration and ratio that they enhance osteoblast production, and methods of preparation and use thereof, are disclosed. The compositions can be included in implantable devices that are capable of inducing tissue formation in autogeneic, allogeneic and xenogeneic implants, for example as coatings and/or matrix materials. Examples of such devices include prosthetic implants, sutures, stents, screws, plates, tubes, and the like. Aqueous extracts of the bioactive glass compositions, which extracts are capable of stimulating osteoblast production, are also disclosed. The compositions can be used, for example, to induce local tissue formation from a progenitor cell in a mammal, for accelerating allograft repair in a mammal, for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site, and for treating tissue degenerative conditions.

ACCESSION NUMBER: 2004:13078 USPATFULL
TITLE: Use of bioactive glass compositions to stimulate osteoblast production
INVENTOR(S): Hench, Larry L, London, UNITED KINGDOM
Polak, Julia M, London, UNITED KINGDOM
Buttery, Lee D.k., London, UNITED KINGDOM
Xynos, Ioannis D, Nafplion, GREECE
Maroothynaden, Jason, London, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009598	A1	20040115	
APPLICATION INFO.:	US 2003-332731	A1	20030707	(10)
	WO 2001-US21801		20010711	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 1301

L8 ANSWER 6 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and

synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L8 ANSWER 7 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)
	US 2000-249216P	20001117 (60)

US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)

	US 2000-256719P 20001205 (60)
	US 2000-250160P 20001201 (60)
	US 2000-251989P 20001208 (60)
	US 2000-250391P 20001201 (60)
	US 2000-254097P 20001211 (60)
	US 2000-231968P 20000912 (60)
	US 2000-226279P 20000818 (60)
	US 2000-186350P 20000302 (60)
	US 2000-184664P 20000224 (60)
	US 2000-189874P 20000316 (60)
	US 2000-198123P 20000418 (60)
	US 2000-227009P 20000823 (60)
	US 2000-235484P 20000926 (60)
	US 2000-190076P 20000317 (60)
	US 2000-209467P 20000607 (60)
	US 2000-205515P 20000519 (60)
	US 2001-259678P 20010105 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	32038

L8 ANSWER 8 OF 214 USPATFULL on STN

TI Methods for the treatment of carcinoma

AB The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, such as renal cell carcinoma, and may act as predictors of the prognosis of tumor treatment. The present invention is directed to novel methods of diagnosing and treating tumor, such as renal cell carcinoma or Wilms tumor.

ACCESSION NUMBER:	2004:12653 USPATFULL
TITLE:	Methods for the treatment of carcinoma
INVENTOR(S):	Gerritsen, Mary E., San Mateo, CA, UNITED STATES Peale, Franklin V., JR., San Carlos, CA, UNITED STATES Wu, Thomas D., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S):	GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009171	A1	20040115
APPLICATION INFO.:	US 2003-372683	A1	20030221 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-271690, filed on 16 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344534P	20011018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	

LINE COUNT: 6662

L8 ANSWER 9 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L8 ANSWER 10 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and

function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7343 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)

US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)

US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27694
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:7341 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)

US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)

	US 2000-246610P	20001108 (60)
	US 2000-246611P	20001108 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-231968P	20000912 (60)
	US 2000-226279P	20000818 (60)
	US 2000-186350P	20000302 (60)
	US 2000-184664P	20000224 (60)
	US 2000-189874P	20000316 (60)
	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	28742	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 214 USPATFULL on STN

TI Functional MRI agents for cancer imaging

AB The invention relates to novel magnetic resonance imaging contrast agents for imaging cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:4285 USPATFULL		
TITLE:	Functional MRI agents for cancer imaging		
INVENTOR(S):	Meade, Thomas J., Altadena, CA, United States Fraser, Scott, La Canada, CA, United States Jacobs, Russell, Arcadia, CA, United States		
PATENT ASSIGNEE(S):	Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673333	B1	20040106
APPLICATION INFO.:	US 2000-715859		20001117 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-201816P		20000504 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Hartley, Michael G.		
LEGAL REPRESENTATIVE:	Dorsey & Whitney LLP, Silva, Robin M., Kossiak, Renee M.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2422		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 214 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 214 USPATFULL on STN
TI Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
AB This invention relates to genes identified from human chromosome 20p13-p12, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and

isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.

ACCESSION NUMBER: 2004:2447 USPATFULL
TITLE: Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES
Little, Randall D., Newtonville, MA, UNITED STATES
Eerdewegh, Paul Van, Weston, MA, UNITED STATES
Dupuis, Josee, Newton, MA, UNITED STATES
Del Mastro, Richard G., Norfolk, MA, UNITED STATES
Simon, Jason, Westfield, NJ, UNITED STATES
Allen, Kristin, Hopkinton, MA, UNITED STATES
Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002470	A1	20040101
APPLICATION INFO.:	US 2002-277216	A1	20021017 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-126022, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN & FINNEGAN, L.L.P., 345 PARK AVENUE, NEW YORK, NY, 10154
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 162 Drawing Page(s)
LINE COUNT: 15810

L8 ANSWER 15 OF 214 USPATFULL on STN
TI Detection and modulation of Slit and roundabount (Robo) mediated angiogenesis and uses thereof
AB This invention is generally in the field of methods for diagnosis, treatment and prevention of various disorders involving the Slit2 mediated angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:335332 USPATFULL
TITLE: Detection and modulation of Slit and roundabount (Robo) mediated angiogenesis and uses thereof
INVENTOR(S): Geng, Jian-Guo, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236210	A1	20031225
APPLICATION INFO.:	US 2003-386386	A1	20030310 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362485P	20020308 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334955 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)

US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)

US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)

US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)

US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)

US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)

US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)

	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-231968P	20000912 (60)
	US 2000-226279P	20000818 (60)
	US 2000-186350P	20000302 (60)
	US 2000-184664P	20000224 (60)
	US 2000-189874P	20000316 (60)
	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	20415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 214 USPATFULL on STN

TI Compositions and methods for systemic inhibition of cartilage degradation

AB Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:334713 USPATFULL		
TITLE:	Compositions and methods for systemic inhibition of cartilage degradation		
INVENTOR(S):	Demopulos, Gregory A., Mercer Island, WA, UNITED STATES Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES Herz, Jeffrey M., Mill Creek, WA, UNITED STATES		
PATENT ASSIGNEE(S):	Omeros Corporation (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235589	A1	20031225
APPLICATION INFO.:	US 2003-356649	A1	20030131 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, PENDING		

NUMBER	DATE

PRIORITY INFORMATION:	US 2002-353552P	20020201 (60)
	US 1999-144904P	19990721 (60)
	US 1998-107256P	19981105 (60)
	US 1998-105026P	19981020 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OMEROS MEDICAL SYSTEMS, INC., 1420 FIFTH AVENUE, SUITE 2675, SEATTLE, WA, 98101
NUMBER OF CLAIMS: 155
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 6575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel endocrine related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "endocrine antigens," and the use of such endocrine antigens for detecting disorders of the endocrine system, particularly the presence of cancers of the endocrine system and endocrine cancer metastases. More specifically, isolated endocrine associated nucleic acid molecules are provided encoding novel endocrine associated polypeptides. Novel endocrine polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human endocrine associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the endocrine system, including cancers of the endocrine system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:330759 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232975	A1	20031218
APPLICATION INFO.:	US 2002-74024	A1	20020214 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764895, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)

US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 21828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 214 USPATFULL on STN
TI Proteases
AB The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:330138 USPATFULL
TITLE: Proteases
INVENTOR(S): Delegeane, Angelo M., Milpitas, CA, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Hafalia, April J. A., Santa Clara, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Arvizu, Chandra S., San Jose, CA, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Das, Debopriya, Mountain View, CA, UNITED STATES
Kallick, Deborah A., Portola Valley, CA, UNITED STATES
Nguyen, Danniel B., San Jose, CA, UNITED STATES
Lee, Ernestine A., Castro Valley, CA, UNITED STATES
Khan, Farrah A., Glen View, IL, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Au-Young, Janice, Brisbane, CA, UNITED STATES
Griffin, Jennifer A., Fremont, CA, UNITED STATES
Policky, Jennifer L., San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Mountain View, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Kearney, Liam, San Francisco, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Borowsky, Mark L., Redwood City, CA, UNITED STATES
Sanjanwala, Madhusudan, Los Altos, CA, UNITED STATES
Yao, Monique G., Carmel, IN, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Lee, Sally, San Jose, CA, UNITED STATES
Todd, Stephen, San Francisco, CA, UNITED STATES
Lo, Terence P., Foster City, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
PATENT ASSIGNEE(S): Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232349	A1	20031218
APPLICATION INFO.:	US 2002-274639	A1	20021018 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2001-US22397, filed on 17 Jul 2001, PENDING

NUMBER DATE

```
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-220063P    20000721 (60)
                         US 2000-221680P    20000728 (60)
                         US 2000-223544P    20000804 (60)
                         US 2000-224717P    20000811 (60)
                         US 2000-225988P    20000816 (60)
                         US 2000-227568P    20000823 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    INCYTE CORPORATION (formerly known as Incyte, Genomics,
                         Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS:        86
EXEMPLARY CLAIM:         1
LINE COUNT:              8959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
     ON 29 JAN 2004
L1          5340 S TIMP-1
L2             1 S CEREBUS PROTEIN
L3         10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4         41802 S INTERFERON ALPHA
L5         14602 S INTERFERON BETA
L6        258098 S ALBUMIN
L7         30354 S L6 AND FUSION
L8           214 S L7 AND L1
L9             0 S L7 AND L2
L10          636 S L7 AND L3
L11         1550 S L7 AND L4
L12         1361 S L7 AND L5
L13            0 S L6 AND L2

=> d l10 ti abs ibib 1-20

L10  ANSWER 1 OF 636  USPATFULL on STN
TI     Modulation of neural stem cells and neural progenitor cells
AB     The invention relates generally to methods of influencing central
       nervous system cells to produce progeny useful in the treatment of CNS
       disorders. More specifically, the invention includes methods of exposing
       a patient suffering from such a disorder to a reagent that modulates the
       proliferation, migration, differentiation and survival of central
       nervous system cells via S1P or LPA signaling. These methods are useful
       for reducing at least one symptom of the disorder.

ACCESSION NUMBER:        2004:19358  USPATFULL
TITLE:                   Modulation of neural stem cells and neural progenitor
                         cells
INVENTOR(S):             Lindquist, Per, Staltradsvagen 21, SWEDEN
                         Mercer, Alex, Staltradsvagen 15, SWEDEN
                         Ronnholm, Harriet, Tornslingan 8, 1tr, SWEDEN
                         Wikstrom, Lilian, Stjarnfallsvagen 9, SWEDEN

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004014662      A1   20040122
APPLICATION INFO.:       US 2003-434943     A1   20030508  (10)

                               NUMBER        DATE
                         ----------------- --------
```

PRIORITY INFORMATION: US 2002-379114P 20020508 (60)
US 2002-393159P 20020702 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., 666 Third Avenue, 24th Floor, New York, NY, 10017
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3175

L10 ANSWER 2 OF 636 USPATFULL on STN
TI Novel carcinoma-related genes and polypeptides and methods of use thereof
AB Novel nucleic acids and polypeptides encoded thereby are provided that are highly duplicated and overexpressed in squamous cell carcinomas of a variety of tissues. Antibodies specific for binding the novel polypeptides are also provided. The invention further discloses several assays for gene duplication and overexpression of the novel gene and excessive production of the novel polypeptide in a sample. These assays permit assessing copy number in a sample from a subject, and contribute to the diagnosis, prognosis and development of therapeutic strategy for a pathology such as squamous cell carcinoma in a subject.

ACCESSION NUMBER: 2004:13021 USPATFULL
TITLE: Novel carcinoma-related genes and polypeptides and methods of use thereof
INVENTOR(S): Singh, Bhuvanesh, New York, NY, UNITED STATES
Reddy, Pabbathi Gopal, Gangadhara Mandal, INDIA
Reddy, Pabbathi Thirumal, Gangadhara Mandal, INDIA LR
PATENT ASSIGNEE(S): Memorial Sloan-Kettering Cancer Center (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009541	A1	20040115	
APPLICATION INFO.:	US 2003-361725	A1	20030210	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-355009P	20020208	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Proteus Patent Practice LLC, P. O. Box 1867, New Haven, CT, 06508
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 6217

L10 ANSWER 3 OF 636 USPATFULL on STN
TI Methods and reagents for dendritic localization of polynucleotides
AB The present invention provides for a recombinant nucleic acid molecule comprising a region of a calcium-calmodulin dependent kinase II.alpha. promoter operatively linked to a gene of interest. The region of a calcium-calmodulin dependent kinase II.alpha. promoter may comprise an 8.5 kilobase nucleic acid sequence which corresponds to the nucleic acid sequence of ATCC Accession No. _____, designated pMM281. The present invention also provides a human cell line which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase II.alpha. promoter region which has a nucleotide sequence corresponding to the sequence of ATCC Accession

No. _____, designated pMM281. The present invention also provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII.alpha. promoter (ATCC Accession No. _____), introduced into the mammal, or an ancestor thereof, at an embryonic stage. Another embodiment of the present invention is a method of evaluating whether a compound is effective in treating symptoms of a neurological disorder in a subject which comprises: (a) administering the compound to the transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII.alpha. promoter, and (b) comparing the neurological function the mammal in step (a) with neurological function of the transgenic mammal in the absence of the compound, thereby determining whether the compound is effective in treating symptoms of the neurological disorder in a subject.

ACCESSION NUMBER: 2004:12977 USPATFULL
TITLE: Methods and reagents for dendritic localization of polynucleotides
INVENTOR(S): Kandel, Eric R., Riverdale, NY, UNITED STATES
Mayford, Mark, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009497	A1	20040115
APPLICATION INFO.:	US 2003-341999	A1	20030114 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-969137, filed on 12 Nov 1997, GRANTED, Pat. No. US 6509190
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John P. White, Esq., Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 56 Drawing Page(s)
LINE COUNT: 4900

L10 ANSWER 4 OF 636 USPATFULL on STN
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AB The invention relates to compositions, kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer.

ACCESSION NUMBER: 2004:12961 USPATFULL
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
INVENTOR(S): Schlegel, Robert, Auburndale, MA, UNITED STATES
Endege, Wilson O., Norwood, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009481	A1	20040115
APPLICATION INFO.:	US 2002-166883	A1	20020611 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297285P	20010611 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 15572

L10 ANSWER 5 OF 636 USPATFULL on STN
TI Cardiotrophin and uses therefor
AB Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFR.beta.. These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFR.beta.. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFR.beta..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:7778 USPATFULL
TITLE: Cardiotrophin and uses therefor
INVENTOR(S): Baker, Joffre, El Granada, CA, UNITED STATES
Chien, Kenneth, La Jolla, CA, UNITED STATES
King, Kathleen, Pacifica, CA, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Wood, William, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006018	A1	20040108
APPLICATION INFO.:	US 2003-407303	A1	20030403 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-724772, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1997-797014, filed on 7 Feb 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-49998P	19960214 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 5602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 636 USPATFULL on STN
TI Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides
AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human DCAL-Hy polypeptides. Other aspects of the invention include vectors containing processes for producing novel human DCAL-Hy polypeptides, and antibodies specific for such polypeptides. Targeting DCAL-Hy using DCAL-Hy polypeptides, nucleic acids encoding for DCAL-Hy polypeptides, anti-DCAL-Hy antibodies, and other binding peptides and small molecules provides a method of killing or inhibiting that growth of cancer cells that express the DCAL-Hy protein. Methods of therapy and diagnosis of disorders associated with DCAL-Hy protein-expressing cells, such as DCAL-Hy, are described.

ACCESSION NUMBER: 2004:7358 USPATFULL

TITLE: Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

INVENTOR(S): Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Goodrich, Ryle W., Los Angeles, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005592	A1	20040108
APPLICATION INFO.:	US 2003-379127	A1	20030303 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 7657

L10 ANSWER 7 OF 636 USPATFULL on STN
TI Method for treating inflammation
AB A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:7087 USPATFULL
TITLE: Method for treating inflammation
INVENTOR(S): Thompson, Penny, Snohomish, WA, UNITED STATES
Foster, Donald C., Lake Forest Park, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Madden, Karen L., Bellevue, WA, UNITED STATES
Kelly, James D., Mercer Island, WA, UNITED STATES
Sprecher, Cindy A., Seattle, WA, UNITED STATES
Blumberg, Hal, Seattle, WA, UNITED STATES
Eagan, Maribeth A., Seattle, WA, UNITED STATES
Jaspers, Stephen R., Edmonds, WA, UNITED STATES
Chandrasekher, Yasmin A., Mercer Island, WA, UNITED STATES
Novak, Julia E., Bainbridge Island, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005320	A1	20040108
APPLICATION INFO.:	US 2003-424658	A1	20030428 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-746359, filed on 22 Dec 2000, GRANTED, Pat. No. US 6610286

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-171969P	19991223 (60)
	US 2000-213341P	20000622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Shelby J. Walker, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 3489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 636 USPATFULL on STN
TI Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AB Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:7084 USPATFULL
TITLE: Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
INVENTOR(S): Dedera, Douglas, Castro Valley, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005317	A1	20040108
APPLICATION INFO.:	US 2002-327413	A1	20021219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-78080, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. WO 2001-US2613, filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-645476, filed on 24 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 636 USPATFULL on STN
TI Fc region variants
AB The present invention provides polypeptide Fe region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.

ACCESSION NUMBER: 2004:2564 USPATFULL
TITLE: Fc region variants
INVENTOR(S): Watkins, Jeffry D., Olivenhain, CA, UNITED STATES
Allan, Barrett, Encinitas, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002587	A1	20040101
APPLICATION INFO.:	US 2003-370749	A1	20030220 (10)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2002-358161P	20020220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	5292	

L10 ANSWER 10 OF 636 USPATFULL on STN

TI Methods for making recombinant proteins using apoptosis inhibitors

AB The invention provided improved methods of making and producing recombinant proteins in in vitro cultures of host cells using apoptosis inhibitors. The use of one or more apoptosis inhibitors in the methods can reduce apoptosis in the cell cultures and markedly improve yield of the desired recombinant proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:2118 USPATFULL		
TITLE:	Methods for making recombinant proteins using apoptosis inhibitors		
INVENTOR(S):	Dixit, Vishva, Los Altos Hills, CA, UNITED STATES Hamilton, Robert W., San Carlos, CA, UNITED STATES Goor, Jana van de, Foster City, CA, UNITED STATES		
PATENT ASSIGNEE(S):	Genentech, Inc. (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002139	A1	20040101
APPLICATION INFO.:	US 2003-607882	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-668924, filed on 25 Sep 2000, GRANTED, Pat. No. US 6586206		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-156232P	19990927 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Genentech, Inc., Attn: Diane L. Marschang, 1 DNA Way, South San Francisco, CA, 94080-4990		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	1549		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 636 USPATFULL on STN

TI Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

AB The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin .alpha..sub.V.beta..sub.3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin .alpha..sub.V.beta..sub.3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin .alpha..sub.V.beta..sub.3 alone or in combination with standard and experimental therapies for treatment or

prevention of cancer. Also included are methods for screening for epitope-specific Integrin .alpha..sub.V.beta..sub.3 antagonists which can be used according to the methods of the invention. In addition, methods for facilitating the use of Integrin .alpha..sub.V.beta..sub.3 antagonists in the analysis of Integrin .alpha..sub.V.beta..sub.3 expression in biopsies of animal model and clinical study samples are also contemplated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:1816 USPATFULL
TITLE:	Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
INVENTOR(S):	Woessner, Richard, Lafayette, CO, UNITED STATES Kiener, Peter, Doylestwon, PA, UNITED STATES Dormitzer, Melissa, Germantown, MD, UNITED STATES Walsh, William, Sharpsburg, MD, UNITED STATES Heinrichs, Jon, North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S):	MedImmune, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004001835	A1	20040101	
APPLICATION INFO.:	US 2003-379189	A1	20030304	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-361859P	20020304	(60)
	US 2002-370398P	20020405	(60)
	US 2003-444265P	20030130	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS:	44
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Page(s)
LINE COUNT:	6588

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 636 USPATFULL on STN

TI Methods of treatment using specific binding agents of human angiopoietin-2

AB Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:335315 USPATFULL
TITLE:	Methods of treatment using specific binding agents of human angiopoietin-2
INVENTOR(S):	Oliner, Jonathan Daniel, Newbury Park, CA, UNITED STATES Min, Hosung, Newbury Park, CA, UNITED STATES
PATENT ASSIGNEE(S):	Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003236193	A1	20031225	
APPLICATION INFO.:	US 2003-410998	A1	20030409	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-269695, filed on 10 Oct 2002, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414155P	20020927 (60)
	US 2001-328624P	20011011 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: U.S Patent Operations/[SNB], AMGEN, INC., Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 9524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 636 USPATFULL on STN
TI Vascularized organized tissues and uses thereof
AB The invention relates to organized tissues that are implanted into an organism wherein they become vascularized. The invention also relates to methods of using an organized tissue that is vascularized following implantation into an organism, for delivery of a bioactive compound. The invention also relates to methods of producing an organized tissue that is vascularized following implantation into an organism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334686 USPATFULL
TITLE: Vascularized organized tissues and uses thereof
INVENTOR(S): Vandenburgh, Herman H., Providence, RI, UNITED STATES
Valentini, Robert F., Cranston, RI, UNITED STATES
Wang, Xiao, Providence, RI, UNITED STATES
Shansky, Janet, Barrington, RI, UNITED STATES
Ferland, Paulette, Tiverton, RI, UNITED STATES
DelTatto, Michael, Bristol, RI, UNITED STATES
PATENT ASSIGNEE(S): Cell Based Delivery Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003235561	A1	20031225	
APPLICATION INFO.:	US 2002-281765	A1	20021028	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-391330P	20020625 (60)
	US 2002-399605P	20020730 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 85
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5322
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 636 USPATFULL on STN
TI Central airway administration for systemic delivery of therapeutics
AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products

have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

ACCESSION NUMBER: 2003:334661 USPATFULL
TITLE: Central airway administration for systemic delivery of therapeutics
INVENTOR(S): Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES
Simister, Neil E., Wellesley, MA, UNITED STATES
Bitonti, Alan J., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., Boston, MA, UNITED STATES, 02115 (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, UNITED STATES, 02115 (U.S. corporation)
Brandeis University, Waltham, MA, UNITED STATES, 02254 (U.S. corporation)
Syntonix Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235536	A1	20031225
APPLICATION INFO.:	US 2003-435608	A1	20030509 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364482P	20020315 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211
NUMBER OF CLAIMS: 127
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 4042

L10 ANSWER 15 OF 636 USPATFULL on STN
TI Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
AB The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:331452 USPATFULL
TITLE: Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
INVENTOR(S): Snow, Alan D., Lynnwood, WA, UNITED STATES
Fukuchi, Ken-Ichiro, Birmingham, AL, UNITED STATES
Hassell, John, Tampa, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003233669	A1	20031218
APPLICATION INFO.:	US 2003-384172	A1	20030305 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-536231, filed on 27 Mar 2000, GRANTED, Pat. No. US 6563016 Continuation of Ser. No. US 1997-870987, filed on 6 Jun 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17830P	19960606 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PATRICK M. DWYER, PROTEOTECH, INC, SUITE 114, 1818 WESTLAKE AVENUE N, SEATTLE, WA, 98109
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 2761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 636 USPATFULL on STN
TI Method for identifying compounds which affect synaptogenesis
AB A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excitory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excitory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression. A method is provided for treating a subject with a disorder associated with an increase in a function or expression of Narp, including administering to the subject a therapeutically effective of a compound that inhibits Narp function or expression. A method is provided for treating a patient having or at risk of having a disorder associated with decreased Narp expression. The method includes introducing into a cell of a patient having a disorder associated with decreased Narp expression or function a polynucleotide sequence encoding a Narp polypeptide operatively linked to a promoter. A method is provided for treating a subject having a deficiency in a neuron's immediate early gene responsiveness to a stimulus. The method includes administering a nucleic acid encoding a Narp polypeptide to said subject, wherein the administration results in amelioration of the deficiency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:330561 USPATFULL
TITLE: Method for identifying compounds which affect synaptogenesis
INVENTOR(S): Worley, Paul, Baltimore, MD, UNITED STATES
O'Brien, Richard, Baltimore, MD, UNITED STATES
Xu, DeSheng, Towson, MD, UNITED STATES
Huganir, Richard L., Baltimore, MD, UNITED STATES
PATENT ASSIGNEE(S): THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2003232776 A1 20031218
APPLICATION INFO.: US 2002-299957 A1 20021118 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-328710, filed on 9 Jun 1999, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GRAY CARY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 636 USPATFULL on STN
TI Treatment of inner ear hair cells
AB Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration of inner ear tissue, particularly inner ear hair cells. In addition, provided are compositions and methods for prophylactic or therapeutic treatment of a mammal afflicted with an inner ear disorder or condition, particularly for hearing impairments involving hair cell damage, loss, or degeneration, by administration of a therapeutically effective amount of IGF-1 or FGF-2, or their agonists, alone or in combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:330544 USPATFULL
TITLE: Treatment of inner ear hair cells
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232759	A1	20031218
APPLICATION INFO.:	US 2003-458039	A1	20030609 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-644368, filed on 23 Aug 2000, PENDING Division of Ser. No. US 1997-963596, filed on 31 Oct 1997, GRANTED, Pat. No. US 6156728
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 2082
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 636 USPATFULL on STN
TI Proliferated cell lines and uses thereof
AB The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferation cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferation cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and

drug development.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:330537 USPATFULL			
TITLE:	Proliferated cell lines and uses thereof			
INVENTOR(S):	Freeman, Thomas B., Tampa, FL, UNITED STATES Caviedes, Pablo, Santiago, CHILE Caviedes, Raul, Santiago, CHILE Sanberg, Paul R., Spring Hill, FL, UNITED STATES Cameron, Don F., Lutz, FL, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003232752	A1	20031218	
APPLICATION INFO.:	US 2003-359854	A1	20030207	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2002-355157P		20020208	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669			
NUMBER OF CLAIMS:	93			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	30 Drawing Page(s)			
LINE COUNT:	4025			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 636 USPATFULL on STN

TI Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same

AB The present invention provides MICAL and MICAL-Like polypeptides and polynucleotides. Also provided are methods that for identifying agents that affect axon growth and placement. Furthermore, provided herein are methods for affecting axon growth and placement.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:330208 USPATFULL			
TITLE:	Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same			
INVENTOR(S):	Kolodkin, Alex L., Baltimore, MD, UNITED STATES Terman, Jon R., Baltimore, MD, UNITED STATES Mao, Tiany, Parkville, MD, UNITED STATES Pasterkamp, Ronald J., Baltimore, MD, UNITED STATES Yu, Hung-Hsiang, Lynnwood, WA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003232419	A1	20031218	
APPLICATION INFO.:	US 2003-359012	A1	20030204	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2002-354178P		20020204	(60)
	US 2002-384302P		20020530	(60)
	US 2002-388325P		20020613	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	LISA A. HAILE, J.D., PH.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133			

NUMBER OF CLAIMS: 153
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Page(s)
LINE COUNT: 10590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 636 USPATFULL on STN
TI Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:329847 USPATFULL
TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
INVENTOR(S): Dubensky, Thomas W., JR., Del Mar, CA, UNITED STATES
Polo, John M., Encinitas, CA, UNITED STATES
Belli, Barbara A., San Diego, CA, UNITED STATES
Schlesinger, Sondra, St. Louis, MO, UNITED STATES
Drvga, Sergey A., Fort Collins, CO, UNITED STATES
Frolov, Ilya, St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232058	A1	20031218
APPLICATION INFO.:	US 2003-391441	A1	20030317 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-507362, filed on 18 Feb 2000, GRANTED, Pat. No. US 6592874 Division of Ser. No. US 1997-944465, filed on 6 Oct 1997, GRANTED, Pat. No. US 6451592 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 63 Drawing Page(s)
LINE COUNT: 8258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004
L1 5340 S TIMP-1
L2 1 S CEREBUS PROTEIN

```
L3         10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4         41802 S INTERFERON ALPHA
L5         14602 S INTERFERON BETA
L6        258098 S ALBUMIN
L7         30354 S L6 AND FUSION
L8           214 S L7 AND L1
L9             0 S L7 AND L2
L10          636 S L7 AND L3
L11         1550 S L7 AND L4
L12         1361 S L7 AND L5
L13            0 S L6 AND L2

=> d l11 ti abs ibib 1-20

L11  ANSWER 1 OF 1550     MEDLINE on STN
TI   Pharmacokinetic and pharmacodynamic studies of a human serum
     albumin-interferon-alpha fusion
     protein in cynomolgus monkeys.
AB   Interferon-alpha (IFN-alpha) is indicated for the
     treatment of certain viral infections including hepatitis B and C, and
     cancers such as melanoma.  The short circulating half-life of unmodified
     IFN-alpha makes frequent dosing (daily or three times weekly) over an
     extended period (6-12 months or more) necessary.  To improve the
     pharmacokinetics of IFN-alpha and decrease dosing frequency, IFN-alpha was
     fused to human serum albumin producing a new protein, Albuferon.
     In vitro comparisons of Albuferon and IFN-alpha showed similar antiviral
     and antiproliferative activities, although Albuferon was less potent on a
     molar basis than IFN-alpha.  Pharmacokinetic and pharmacodynamic
     properties of the fusion protein were enhanced in monkeys.
     After a single intravenous injection (30 microg/kg,) clearance was 0.9
     ml/h/kg, and the terminal half-life was 68 h.  After 30 microg/kg
     subcutaneous injection, apparent clearance (clearance divided by
     bioavailability) was 1.4 ml/h/kg, the terminal half-life was 93 h, and
     bioavailability was 64%.  The rate of clearance of Albuferon was
     approximately 140-fold slower, and the half-life 18-fold longer, than for
     IFN-alpha given by the subcutaneous route in other monkey studies.  Sera
     from Albuferon-treated monkeys demonstrated dose-related antiviral
     activity for > or =8 days based on an in vitro bioassay, whereas antiviral
     activity from IFN-alpha-treated animals was only slightly elevated
     relative to vehicle on day 0.  Significant increases in
     2',5'-oligoadenylate synthetase mRNA relative to IFN-alpha- or
     vehicle-treated animals were maintained for > or =10 days after
     subcutaneous dosing.  The improved pharmacokinetics of Albuferon are
     accompanied by an improved pharmacodynamic response suggesting that
     Albuferon may offer the benefits of less frequent dosing and a potentially
     improved efficacy profile compared with IFN-alpha.
ACCESSION NUMBER:    2002641106     MEDLINE
DOCUMENT NUMBER:     22276264   PubMed ID: 12388634
TITLE:               Pharmacokinetic and pharmacodynamic studies of a human
                     serum albumin-interferon-alpha
                     fusion protein in cynomolgus monkeys.
AUTHOR:              Osborn Blaire L; Olsen Henrik S; Nardelli Bernardetta;
                     Murray James H; Zhou Joe X H; Garcia Andrew; Moody Gordon;
                     Zaritskaya Liubov S; Sung Cynthia
CORPORATE SOURCE:    Human Genome Sciences, Inc., 9410 Key West Avenue,
                     Rockville, MD 20850, USA.. blaire_osborn@hgsi.com
SOURCE:              JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,
                     (2002 Nov) 303 (2) 540-8.
                     Journal code: 0376362. ISSN: 0022-3565.
PUB. COUNTRY:        United States
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
ENTRY MONTH:         200211
```

ENTRY DATE: Entered STN: 20021029
Last Updated on STN: 20021211
Entered Medline: 20021122

L11 ANSWER 2 OF 1550 USPATFULL on STN
TI Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
AB The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

ACCESSION NUMBER: 2004:21589 USPATFULL
TITLE: Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
INVENTOR(S): Gately, Maurice Kent, Montville, NJ, United States
Gubler, Ulrich Andreas, Glen Ridge, NJ, United States
Hulmes, Jeffrey David, Ringwood, NJ, United States
Podlaski, Frank John, New City, NY, United States
Stern, Alvin Seth, Passaic Park, NJ, United States
Chizzonite, Richard Anthony, South Kent, CT, United States
Pan, Yu-Ching Eugene, Pine Brook, NJ, United States
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683046	B1	20040127
APPLICATION INFO.:	US 1995-459151		19950602 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-205011, filed on 2 Mar 1994, now abandoned Division of Ser. No. US 1992-857023, filed on 24 Mar 1992, now abandoned Continuation-in-part of Ser. No. US 1990-572284, filed on 27 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-520935, filed on 9 May 1990, now abandoned Continuation-in-part of Ser. No. US 1989-455708, filed on 22 Dec 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Romeo, David S.
ASSISTANT EXAMINER: Murphy, Joseph F.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 2745

L11 ANSWER 3 OF 1550 USPATFULL on STN
TI Methods and compositions for interferon therapy
AB Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions

responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

ACCESSION NUMBER: 2004:19405 USPATFULL
TITLE: Methods and compositions for interferon therapy
INVENTOR(S): Engler, Heidrun, San Diego, CA, UNITED STATES
Nagabhushan, Tattanahalli L., Parsippany, NJ, UNITED STATES
Youngster, Stephen, Piscataway, NJ, UNITED STATES
PATENT ASSIGNEE(S): Canji, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014709	A1	20040122
APPLICATION INFO.:	US 2003-455215	A1	20030604 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-55863, filed on 22 Jan 2002, PENDING Continuation of Ser. No. US 1998-112074, filed on 8 Jul 1998, GRANTED, Pat. No. US 6392069 Continuation-in-part of Ser. No. US 1997-889355, filed on 8 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244 Continuation-in-part of Ser. No. US 2003-454662, filed on 3 Jun 2003, PENDING Continuation of Ser. No. US 2000-650359, filed on 28 Aug 2000, ABANDONED Continuation of Ser. No. US 1997-779627, filed on 7 Jan 1997, GRANTED, Pat. No. US 6165779 Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 2411

L11 ANSWER 4 OF 1550 USPATFULL on STN
TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:19345 USPATFULL
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014649	A1	20040122
APPLICATION INFO.:	US 2002-197919	A1	20020716 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 3468

L11 ANSWER 5 OF 1550 USPATFULL on STN
TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein
AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:19334 USPATFULL
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein
INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014638	A1	20040122
APPLICATION INFO.:	US 2002-197368	A1	20020716 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3569

L11 ANSWER 6 OF 1550 USPATFULL on STN
TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein
AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18847 USPATFULL
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein
INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES

Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014149	A1	20040122	
APPLICATION INFO.:	US 2002-197962	A1	20020716	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3529

L11 ANSWER 7 OF 1550 USPATFULL on STN
TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18846 USPATFULL
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014148	A1	20040122	
APPLICATION INFO.:	US 2002-197945	A1	20020716	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3609

L11 ANSWER 8 OF 1550 USPATFULL on STN
TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18845 USPATFULL
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014147	A1	20040122	
APPLICATION INFO.:	US 2002-197381	A1	20020716	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3513

L11 ANSWER 9 OF 1550 USPATFULL on STN
TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42
AB The present invention provides novel polynucleotides encoding Protease-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ACCESSION NUMBER: 2004:18791 USPATFULL
TITLE: Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nayeem, Akbar, Newtown, PA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014093	A1	20040122	
APPLICATION INFO.:	US 2003-390585	A1	20030314	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364941P	20020314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 19269

L11 ANSWER 10 OF 1550 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)

US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)

US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 26776

L11 ANSWER 11 OF 1550 USPATFULL on STN
TI Treatment with anti-ErbB2 antibodies
AB The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.

ACCESSION NUMBER: 2004:18365 USPATFULL
TITLE: Treatment with anti-ErbB2 antibodies
INVENTOR(S): Kelsey, Stephen M., Montara, CA, UNITED STATES
Sliwkowski, Mark X., San Carlos, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004013667 A1 20040122
APPLICATION INFO.: US 2003-608626 A1 20030627 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-268501, filed on 10 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2000-602812, filed on 23 Jun 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141316P	19990625 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 4076

L11 ANSWER 12 OF 1550 USPATFULL on STN
TI Tumor necrosis factor receptors 6 alpha & 6 beta
AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL
TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta
INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Feng, Ping, Germantown, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)

	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1997-35496P	19970114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	13403	

L11 ANSWER 13 OF 1550 USPATFULL on STN
TI Novel nucleic acids and polypeptides
AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:18355 USPATFULL		
TITLE:	Novel nucleic acids and polypeptides		
INVENTOR(S):	Tang, Y. Tom, San Jose, CA, UNITED STATES Asundi, Vinod, Foster City, CA, UNITED STATES Wehrman, Tom, Stanford, CA, UNITED STATES Yang, Yonghong, San Jose, CA, UNITED STATES Zhang, Jie, Campbell, CA, UNITED STATES Zhou, Ping, Cupertino, CA, UNITED STATES Drmanac, Radoje T., Palo Alto, CA, UNITED STATES Goodrich, Ryle, Los Angeles, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013657	A1	20040122
APPLICATION INFO.:	US 2002-294006	A1	20021112 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US8964, filed on 20 Mar 2002, PENDING Continuation of Ser. No. US 2001-815925, filed on 22 Mar 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	10481		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 1550 USPATFULL on STN
TI Interferon beta-like molecules
AB The invention relates to a conjugate exhibiting interferon .beta. (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been

modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

ACCESSION NUMBER: 2004:18342 USPATFULL
TITLE: Interferon beta-like molecules
INVENTOR(S): Rasmussen, Poul Baad, Soeberg, DENMARK
Drustrup, Joern, Farum, DENMARK
Rasmussen, Grethe, Farum, DENMARK
Pedersen, Anders Hjelholt, Lyngby, DENMARK
Schambye, Hans Thalsgard, Frederiksberg C., DENMARK
Andersen, Kim Vilbour, Broenshoej, DENMARK
Bornaes, Claus, Hellerup, DENMARK
PATENT ASSIGNEE(S): Maxygen ApS (non-U.S. corporation)
Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013644	A1	20040122
APPLICATION INFO.:	US 2003-609296	A1	20030627 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-84706, filed on 26 Feb 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-333	20010301
	DK 1999-1197	19990827
	DK 1999-1691	19991126
	DK 2000-194	20000207
	US 2001-272116P	20010227 (60)
	US 2001-343436P	20011221 (60)
	US 2001-302140P	20010629 (60)
	US 2001-316170P	20010830 (60)
	US 2002-357945P	20020219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CANDESCENT TECHNOLOGIES, 6320 SAN IGNACIO AVE., SAN JOSE, CA, 95119
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5448

L11 ANSWER 15 OF 1550 USPATFULL on STN
TI **Albumin fusion** proteins
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2004010134 A1 20040115
APPLICATION INFO.: US 2001-833245 A1 20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L11 ANSWER 16 OF 1550 USPATFULL on STN
TI 53 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL
TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139
Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L11 ANSWER 17 OF 1550 USPATFULL on STN
TI Recombinant gene containing inverted repeat sequence and utilization thereof
AB The object of the present invention is to improve a method for introducing dsRNA in such a way that RNAi effect is sustained in mammalian (mainly mouse) cells for a long period of time. The present invention provides a recombinant gene which contains inverted repeats of a target gene which can be expressed in mammalian cells.

ACCESSION NUMBER: 2004:13607 USPATFULL
TITLE: Recombinant gene containing inverted repeat sequence and utilization thereof
INVENTOR(S): Katsuki, Motoya, Tokyo, JAPAN
Ishida, Mitsuyoshi, Tokyo, JAPAN
Kato, Minoru, Tokyo, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010130	A1	20040115	
APPLICATION INFO.:	US 2003-296243	A1	20030616	(10)
	WO 2002-JP1554		20020221	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-46089	20010222

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE PLACE, RESTON, VA, 20191
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 3
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 876

L11 ANSWER 18 OF 1550 USPATFULL on STN
TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2004010121 A1 20040115
APPLICATION INFO.: US 2003-333900 A1 20030124 (10)
WO 2001-US8585 20010316
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L11 ANSWER 19 OF 1550 USPATFULL on STN
TI Methods of enhancing immune induction involving MDA-7
AB The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

ACCESSION NUMBER: 2004:13417 USPATFULL
TITLE: Methods of enhancing immune induction involving MDA-7
INVENTOR(S): Chada, Sunil, Missouri City, TX, UNITED STATES
Pataer, Abujiang, Houston, TX, UNITED STATES
Mhashilkar, Abner, Houston, TX, UNITED STATES
Ramesh, Rajagopal, Sugarland, TX, UNITED STATES
Roth, Jack, Houston, TX, UNITED STATES
Swisher, Steve, Fresno, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regent, The University of Texas System (U.S. corporation)
Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009939	A1	20040115	
APPLICATION INFO.:	US 2003-378590	A1	20030303	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-404932P	20020821	(60)
	US 2002-370335P	20020405	(60)
	US 2002-361755P	20020305	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gina N. Shishima, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 6371

L11 ANSWER 20 OF 1550 USPATFULL on STN
TI Macroaggregated **albumin**-polyethyleneimine (MAA-PEI) lung-targeted delivery of respiratory syncytial virus DNA vaccines
AB The present invention provides a composition comprising: 1) macroaggregated **albumin**, 2) a nucleic acid comprising a nucleotide sequence encoding an RSV protein, and 3) polyethylamine (PEI), wherein the MAA, PEI and nucleic acid form a complex. Also provided by the present invention is a method of preventing respiratory syncytial virus (RSV) infection in a subject comprising administering to the subject an amount of a composition of this invention.

ACCESSION NUMBER: 2004:13381 USPATFULL

TITLE: Macroaggregated **albumin**-polyethyleneimine (MAA-PEI) lung-targeted delivery of respiratory syncytial virus DNA vaccines

INVENTOR(S): Tripp, Ralph A., Decatur, GA, UNITED STATES
Harcourt, Jennifer L., Lilburn, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009903	A1	20040115
APPLICATION INFO.:	US 2003-453219	A1	20030602 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-384586P	20020531 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1297

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1	5340	S	TIMP-1
L2	1	S	CEREBUS PROTEIN
L3	10853	S	BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4	41802	S	INTERFERON ALPHA
L5	14602	S	INTERFERON BETA
L6	258098	S	ALBUMIN
L7	30354	S	L6 AND FUSION
L8	214	S	L7 AND L1
L9	0	S	L7 AND L2
L10	636	S	L7 AND L3
L11	1550	S	L7 AND L4
L12	1361	S	L7 AND L5
L13	0	S	L6 AND L2

=> d l12 ti abs ibib 1-20

L12 ANSWER 1 OF 1361 MEDLINE on STN

TI An IFN-beta-**albumin fusion** protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AB The long half-life and stability of human serum **albumin** (HSA) make it an attractive candidate for **fusion** to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene **fusion** of **interferon-beta** (IFN-beta) and HSA.
In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg

was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum **albumin** suggest a clinical opportunity for improved IFN-beta therapy.

ACCESSION NUMBER: 2003128795 MEDLINE
DOCUMENT NUMBER: 22526967 PubMed ID: 12639296
TITLE: An IFN-beta-**albumin fusion** protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
AUTHOR: Sung Cynthia; Nardelli Bernardetta; LaFleur David W; Blatter Erich; Corcoran Marta; Olsen Henrik S; Birse Charles E; Pickeral Oxana K; Zhang Junli; Shah Devanshi; Moody Gordon; Gentz Solange; Beebe Lisa; Moore Paul A
CORPORATE SOURCE: Human Genome Sciences, Inc, Rockville, MD 20850, USA.
SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2003 Jan) 23 (1) 25-36.
Journal code: 9507088. ISSN: 1079-9907.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 20030320
Last Updated on STN: 20030928
Entered Medline: 20030926

L12 ANSWER 2 OF 1361 USPATFULL on STN
TI Methods and compositions for interferon therapy
AB Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

ACCESSION NUMBER: 2004:19405 USPATFULL
TITLE: Methods and compositions for interferon therapy
INVENTOR(S): Engler, Heidrun, San Diego, CA, UNITED STATES
Nagabhushan, Tattanahalli L., Parsippany, NJ, UNITED STATES
Youngster, Stephen, Piscataway, NJ, UNITED STATES
PATENT ASSIGNEE(S): Canji, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014709	A1	20040122
APPLICATION INFO.:	US 2003-455215	A1	20030604 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-55863, filed on 22 Jan 2002, PENDING Continuation of Ser. No. US 1998-112074, filed on 8 Jul 1998, GRANTED, Pat. No. US

6392069 Continuation-in-part of Ser. No. US 1997-889355, filed on 8 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244 Continuation-in-part of Ser. No. US 2003-454662, filed on 3 Jun 2003, PENDING Continuation of Ser. No. US 2000-650359, filed on 28 Aug 2000, ABANDONED Continuation of Ser. No. US 1997-779627, filed on 7 Jan 1997, GRANTED, Pat. No. US 6165779 Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 2411

L12 ANSWER 3 OF 1361 USPATFULL on STN
TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42
AB The present invention provides novel polynucleotides encoding Protease-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ACCESSION NUMBER: 2004:18791 USPATFULL
TITLE: Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nayeem, Akbar, Newtown, PA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014093	A1	20040122	
APPLICATION INFO.:	US 2003-390585	A1	20030314	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-364941P	20020314	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 19269

L12 ANSWER 4 OF 1361 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel

polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)

US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)

US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 26776

L12 ANSWER 5 OF 1361 USPATFULL on STN
TI Immunoreactive peptides from Epstein-Barr virus
AB Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.

ACCESSION NUMBER: 2004:18363 USPATFULL
TITLE: Immunoreactive peptides from Epstein-Barr virus
INVENTOR(S): Smith, Richard S., Salt Lake City, UT, UNITED STATES
Pearson, Gary R., Sedona, AZ, UNITED STATES
Parks, D. Elliot, Del Mar, CA, UNITED STATES
Varghese, Susan Pothen, Melrose, MA, UNITED STATES
PATENT ASSIGNEE(S): Ortho Diagnostic Systems, Inc. (U.S. corporation)
Georgetown University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013665	A1	20040122

APPLICATION INFO.: US 2003-442456 A1 20030521 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 1996-392934, filed on 28 Oct 1996, PENDING A 371 of International Ser. No. WO 1993-US8699, filed on 15 Sep 1993, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EMMA R. DAILEY, WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1490

L12 ANSWER 6 OF 1361 USPATFULL on STN
TI Tumor necrosis factor receptors 6 alpha & 6 beta
AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL
TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta
INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Feng, Ping, Germantown, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)

	US 1999-131279P 19990427 (60)
	US 1999-124092P 19990312 (60)
	US 1999-121774P 19990304 (60)
	US 1997-35496P 19970114 (60)
	US 1997-35496P 19970114 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	40
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	23 Drawing Page(s)
LINE COUNT:	13403

L12 ANSWER 7 OF 1361 USPATFULL on STN

TI **Interferon beta**-like molecules

AB The invention relates to a conjugate exhibiting **interferon** . **beta**. (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

ACCESSION NUMBER:	2004:18342 USPATFULL
TITLE:	**Interferon beta**-like molecules
INVENTOR(S):	Rasmussen, Poul Baad, Soeberg, DENMARK Drustrup, Joern, Farum, DENMARK Rasmussen, Grethe, Farum, DENMARK Pedersen, Anders Hjelholt, Lyngby, DENMARK Schambye, Hans Thalsgard, Frederiksberg C., DENMARK Andersen, Kim Vilbour, Broenshoej, DENMARK Bornaes, Claus, Hellerup, DENMARK
PATENT ASSIGNEE(S):	Maxygen ApS (non-U.S. corporation) Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013644	A1	20040122
APPLICATION INFO.:	US 2003-609296	A1	20030627 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-84706, filed on 26 Feb 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-333	20010301
	DK 1999-1197	19990827
	DK 1999-1691	19991126
	DK 2000-194	20000207
	US 2001-272116P	20010227 (60)
	US 2001-343436P	20011221 (60)
	US 2001-302140P	20010629 (60)
	US 2001-316170P	20010830 (60)
	US 2002-357945P	20020219 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	CANDESCENT TECHNOLOGIES, 6320 SAN IGNACIO AVE., SAN

JOSE, CA, 95119
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5448

L12 ANSWER 8 OF 1361 USPATFULL on STN
TI **Albumin fusion** proteins
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L12 ANSWER 9 OF 1361 USPATFULL on STN
TI 53 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL
TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES

Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010132	A1	20040115	
APPLICATION INFO.:	US 2001-984429	A1	20011030	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139
Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L12 ANSWER 10 OF 1361 USPATFULL on STN
TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010121	A1	20040115	
APPLICATION INFO.:	US 2003-333900	A1	20030124	(10)
	WO 2001-US8585		20010316	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L12 ANSWER 11 OF 1361 USPATFULL on STN
TI Methods of enhancing immune induction involving MDA-7
AB The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

ACCESSION NUMBER: 2004:13417 USPATFULL
TITLE: Methods of enhancing immune induction involving MDA-7
INVENTOR(S): Chada, Sunil, Missouri City, TX, UNITED STATES
Pataer, Abujiang, Houston, TX, UNITED STATES
Mhashilkar, Abner, Houston, TX, UNITED STATES
Ramesh, Rajagopal, Sugarland, TX, UNITED STATES
Roth, Jack, Houston, TX, UNITED STATES
Swisher, Steve, Fresno, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regent, The University of Texas System (U.S. corporation)
Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009939	A1	20040115	
APPLICATION INFO.:	US 2003-378590	A1	20030303	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-404932P	20020821	(60)
	US 2002-370335P	20020405	(60)
	US 2002-361755P	20020305	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gina N. Shishima, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 6371

L12 ANSWER 12 OF 1361 USPATFULL on STN
TI Polynucleotides encoding a novel intracellular chloride channel-related polypeptide
AB The present invention describes the novel human intracellular chloride ion channel-related protein HCLI and its encoding polynucleotide. Also described are expression vectors, host cells, antisense molecules, and antibodies associated with the HCLI polynucleotide and/or polypeptide of this invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders or diseases associated with abnormal biological activity of HCLI are described, as are methods for screening for modulators, e.g., agonists or antagonists, of HCLI activity and/or function.

ACCESSION NUMBER: 2004:13393 USPATFULL
TITLE: Polynucleotides encoding a novel intracellular chloride channel-related polypeptide
INVENTOR(S): Chang, Han, Princeton Junction, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., Somerset, NJ, UNITED STATES

Rich, Adam, Yardley, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009915	A1	20040115
APPLICATION INFO.:	US 2003-384919	A1	20030306 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362257P	20020306 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 7702

L12 ANSWER 13 OF 1361 USPATFULL on STN

TI Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, **fusion** proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

ACCESSION NUMBER: 2004:13033 USPATFULL
TITLE: Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor
INVENTOR(S): Glucksmann, Maria A., Lexington, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Kapeller-Libermann, Rosanna, Chestnut Hill, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009553	A1	20040115
APPLICATION INFO.:	US 2003-426776	A1	20030430 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-229662, filed

on 28 Aug 2002, PENDING Division of Ser. No. US 2001-795691, filed on 28 Feb 2001, GRANTED, Pat. No. US 6465230 Continuation-in-part of Ser. No. US 2002-105992, filed on 25 Mar 2002, PENDING Continuation of Ser. No. US 1999-406045, filed on 27 Sep 1999, GRANTED, Pat. No. US 6451994 Continuation-in-part of Ser. No. US 2002-314881, filed on 9 Dec 2002, PENDING Continuation of Ser. No. US 2001-773426, filed on 31 Jan 2001, GRANTED, Pat. No. US 6534302 Continuation-in-part of Ser. No. US 2000-495823, filed on 31 Jan 2000, PENDING Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2002-284014, filed on 30 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-284059, filed on 30 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-185517P	20000228 (60)
	US 1999-161188P	19991022 (60)
	US 2001-335003P	20011031 (60)
	US 2001-335037P	20011031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 24534

L12 ANSWER 14 OF 1361 USPATFULL on STN
TI Export and modification of (poly)peptides in the lantibiotic way
AB The invention includes a method for harvesting a polypeptide produced by a host cell, wherein the polypeptide has not undergone intra-cellular post-translational modification, such as dehydration of a serine or a threonine, and/or thioether bridge formation. The invention also includes a method for producing thioether containing peptides and dehydroalanine/dehydrobutyrine-containing peptides, wherein extracellularly thioether rings may be formed.

ACCESSION NUMBER: 2004:13030 USPATFULL
TITLE: Export and modification of (poly)peptides in the lantibiotic way
INVENTOR(S): Moll, Gert Nikolaas, Groningen, NETHERLANDS
Leenhouts, Cornelis Johannes, Haren, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009550	A1	20040115
APPLICATION INFO.:	US 2003-360101	A1	20030207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-77060	20020524

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 3337

L12 ANSWER 15 OF 1361 USPATFULL on STN
TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839,

49937, 49931 and 49933 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, **fusion** proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

ACCESSION NUMBER: 2004:12981 USPATFULL

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009501	A1	20040115
APPLICATION INFO.:	US 2003-377072	A1	20030227 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1
LINE COUNT: 16123

L12 ANSWER 16 OF 1361 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L12 ANSWER 17 OF 1361 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)

US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L12 ANSWER 18 OF 1361 USPATFULL on STN

TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

AB The invention relates to compositions, kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer.

ACCESSION NUMBER: 2004:12961 USPATFULL
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
INVENTOR(S): Schlegel, Robert, Auburndale, MA, UNITED STATES
Endege, Wilson O., Norwood, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009481	A1	20040115	
APPLICATION INFO.:	US 2002-166883	A1	20020611	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297285P	20010611 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15572	

L12 ANSWER 19 OF 1361 USPATFULL on STN

TI Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases

AB Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.

ACCESSION NUMBER:	2004:12959 USPATFULL		
TITLE:	Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases		
INVENTOR(S):	Wohlgemuth, Jay, Palo Alto, CA, UNITED STATES Fry, Kirk, Palo Alto, CA, UNITED STATES Woodward, Robert, Pleasanton, CA, UNITED STATES Ly, Ngoc, San Bruno, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009479	A1	20040115
APPLICATION INFO.:	US 2002-131827	A1	20020424 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-6290, filed on 22 Oct 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296764P	20010608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael R. Ward, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA, 94105-2482	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	19677	

L12 ANSWER 20 OF 1361 USPATFULL on STN

TI Multimeric binding complexes

AB The invention provides multimeric receptor-binding complexes, including chemokine tetramers, useful for recognizing and binding receptors bound to the surface of a wide variety of cells. The binding complexes are useful for identifying and isolating cells according to their specific receptors, screening for cells having a specific receptor or constellation of receptors, and introducing exogenous molecules (e.g., nucleic acids and toxins) into cells. Methods of producing the complexes and other uses are also described.

ACCESSION NUMBER:	2004:12631 USPATFULL		
TITLE:	Multimeric binding complexes		
INVENTOR(S):	Altman, John D., Decatur, GA, UNITED STATES Ravkov, Eugene, Tucker, GA, UNITED STATES		
	NUMBER	KIND	DATE

```
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004009149      A1   20040115
APPLICATION INFO.:       US 2003-376887     A1   20030227  (10)

                                NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 2002-360724P    20020227 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA,
                         02110
NUMBER OF CLAIMS:        36
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      16 Drawing Page(s)
LINE COUNT:              1909


=> d his

     (FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
     ON 29 JAN 2004
L1          5340 S TIMP-1
L2             1 S CEREBUS PROTEIN
L3         10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4         41802 S INTERFERON ALPHA
L5         14602 S INTERFERON BETA
L6        258098 S ALBUMIN
L7         30354 S L6 AND FUSION
L8           214 S L7 AND L1
L9             0 S L7 AND L2
L10          636 S L7 AND L3
L11         1550 S L7 AND L4
L12         1361 S L7 AND L5
L13            0 S L6 AND L2

=> s albumin fusion protein () interferon alpha
L14            5 ALBUMIN FUSION PROTEIN (W) INTERFERON ALPHA

=> d l14 ti abs ibib tot

L14  ANSWER 1 OF 5  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)
```

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L14 ANSWER 2 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or

ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:282700 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Ballance, David J., Berwyn, PA, UNITED STATES Sleep, Darrell, West Bridgford, UNITED KINGDOM Prior, Christopher P., Rosemont, PA, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199043	A1	20031023	
APPLICATION INFO.:	US 2001-832501	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	60			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	18 Drawing Page(s)			
LINE COUNT:	14339			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:244853 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Prior, Christopher P., Rosemont, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004
L1 5340 S TIMP-1
L2 1 S CEREBUS PROTEIN
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4 41802 S INTERFERON ALPHA
L5 14602 S INTERFERON BETA
L6 258098 S ALBUMIN
L7 30354 S L6 AND FUSION
L8 214 S L7 AND L1
L9 0 S L7 AND L2

```
L10          636 S L7 AND L3
L11         1550 S L7 AND L4
L12         1361 S L7 AND L5
L13            0 S L6 AND L2
L14            5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA

=> s albumin fusion protein  () interferon beta
L15            5 ALBUMIN FUSION PROTEIN (W) INTERFERON BETA

=> d l15 ti abs ibib tot

L15  ANSWER 1 OF 5  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

ACCESSION NUMBER:         2004:13611  USPATFULL
TITLE:                    Albumin fusion proteins
INVENTOR(S):              Rosen, Craig A., Laytonsville, MD, UNITED STATES
                          Haseltine, William A., Washington, DC, UNITED STATES

                               NUMBER        KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2004010134      A1   20040115
APPLICATION INFO.:        US 2001-833245     A1   20010412  (9)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2000-256931P    20001221 (60)
                          US 2000-199384P    20000425 (60)
                          US 2000-229358P    20000412 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                          ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:         29
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       18 Drawing Page(s)
LINE COUNT:               25066

L15  ANSWER 2 OF 5  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2003:312278  USPATFULL
TITLE:                    Albumin fusion proteins
```

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:282700 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:244853 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Prior, Christopher P., Rosemont, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	59			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	20 Drawing Page(s)			
LINE COUNT:	13208			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:181414 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703

```
APPLICATION INFO.:      US 2001-833041     A1   20010412  (9)

                                NUMBER         DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 2000-256931P    20001221 (60)
                        US 2000-199384P    20000425 (60)
                        US 2000-229358P    20000412 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                        ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:       29
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     20 Drawing Page(s)
LINE COUNT:             15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
     ON 29 JAN 2004
L1          5340 S TIMP-1
L2             1 S CEREBUS PROTEIN
L3         10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4         41802 S INTERFERON ALPHA
L5         14602 S INTERFERON BETA
L6        258098 S ALBUMIN
L7         30354 S L6 AND FUSION
L8           214 S L7 AND L1
L9             0 S L7 AND L2
L10          636 S L7 AND L3
L11         1550 S L7 AND L4
L12         1361 S L7 AND L5
L13            0 S L6 AND L2
L14            5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA
L15            5 S ALBUMIN FUSION PROTEIN  () INTERFERON BETA

=> s albumin fusion protein () BDNF
L16            1 ALBUMIN FUSION PROTEIN (W) BDNF

=> d l16 ti abs ibib tot

L16  ANSWER 1 OF 1  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2003:312278  USPATFULL
TITLE:                  Albumin fusion proteins
INVENTOR(S):            Rosen, Craig A., Laytonsville, MD, UNITED STATES
                        Haseltine, William A., Washington, DC, UNITED STATES
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s albumin fusion protein () TIMP-1
5 FILES SEARCHED...
L17 5 ALBUMIN FUSION PROTEIN (W) TIMP-1

=> d l17 ti abs ibib tot

L17 ANSWER 1 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L17 ANSWER 2 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-256931P		20001221 (60)
	US 2000-199384P		20000425 (60)
	US 2000-229358P		20000412 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	15415		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:282700 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Ballance, David J., Berwyn, PA, UNITED STATES Sleep, Darrell, West Bridgford, UNITED KINGDOM Prior, Christopher P., Rosemont, PA, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023

APPLICATION INFO.: US 2001-832501 A1 20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:181414 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-256931P		20001221 (60)
	US 2000-199384P		20000425 (60)
	US 2000-229358P		20000412 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	15235		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1	5340	S	TIMP-1
L2	1	S	CEREBUS PROTEIN
L3	10853	S	BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4	41802	S	INTERFERON ALPHA
L5	14602	S	INTERFERON BETA
L6	258098	S	ALBUMIN
L7	30354	S	L6 AND FUSION
L8	214	S	L7 AND L1
L9	0	S	L7 AND L2
L10	636	S	L7 AND L3
L11	1550	S	L7 AND L4
L12	1361	S	L7 AND L5
L13	0	S	L6 AND L2
L14	5	S	ALBUMIN FUSION PROTEIN () INTERFERON ALPHA
L15	5	S	ALBUMIN FUSION PROTEIN () INTERFERON BETA
L16	1	S	ALBUMIN FUSION PROTEIN () BDNF
L17	5	S	ALBUMIN FUSION PROTEIN () TIMP-1

=> s ablumin fusion protein
L18 0 ABLUMIN FUSION PROTEIN

=> s albumin fusion protein
L19 2840 ALBUMIN FUSION PROTEIN

=> d l19 ti abs ibib 1-30

L19 ANSWER 1 OF 2840 MEDLINE on STN
TI An IFN-beta-**albumin fusion protein** that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
AB The long half-life and stability of human serum albumin (HSA) make it an attractive candidate for fusion to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene fusion of interferon-beta (IFN-beta) and HSA. In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum albumin suggest a clinical opportunity for improved IFN-beta therapy.
ACCESSION NUMBER: 2003128795 MEDLINE
DOCUMENT NUMBER: 22526967 PubMed ID: 12639296
TITLE: An IFN-beta-**albumin fusion protein** that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
AUTHOR: Sung Cynthia; Nardelli Bernardetta; LaFleur David W; Blatter Erich; Corcoran Marta; Olsen Henrik S; Birse Charles E; Pickeral Oxana K; Zhang Junli; Shah Devanshi; Moody Gordon; Gentz Solange; Beebe Lisa; Moore Paul A
CORPORATE SOURCE: Human Genome Sciences, Inc, Rockville, MD 20850, USA.
SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2003 Jan) 23 (1) 25-36.
Journal code: 9507088. ISSN: 1079-9907.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 20030320
Last Updated on STN: 20030928
Entered Medline: 20030926

L19 ANSWER 2 OF 2840 MEDLINE on STN
TI Pharmaceutical strategies utilizing recombinant human serum albumin.
AB Gene manipulation techniques open up the possibility of making recombinant human serum albumin (rHSA) or mutants with desirable therapeutic properties and for protein fusion products. rHSA can serve as a carrier in synthetic heme protein, thus reversibly carrying oxygen. Myristoylation of insulin results in a prolonged half-life because of self aggregation and increased albumin binding. Preferential albumin uptake by tumor cells serves as the basis for albumin-anticancer drug conjugate formulation. Furthermore, drug targeting can be achieved by incorporating drugs into albumin microspheres whereas liver targeting can be achieved by conjugating drug with galactosylated or mannosylated albumin. Microspheres and nanoparticles of different sizes can, with or without drugs and/or radioisotopes, be used for drug delivery or diagnostic purposes. In vivo implantation of **albumin fusion**

protein expressing cells encapsulated in HSA-alginate coated beads showed promising results compared to organoids in rats. Chimeric peptide strategy with cationized albumin as the transport can deliver drugs via receptor mediated transcytosis through the blood brain barrier. Gene bearing, albumin microbubbles containing ultrasound contrast agents can non-invasively deliver gene after destruction by ultrasound. Various site-directed mutants of HSA can be tailor made depending on the application required.

ACCESSION NUMBER: 2002326620 MEDLINE
DOCUMENT NUMBER: 22064084 PubMed ID: 12069157
TITLE: Pharmaceutical strategies utilizing recombinant human serum albumin.
AUTHOR: Chuang Victor Tuan Giam; Kragh-Hansen Ulrich; Otagiri Masaki
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
SOURCE: PHARMACEUTICAL RESEARCH, (2002 May) 19 (5) 569-77. Ref: 91
Journal code: 8406521. ISSN: 0724-8741.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200302
ENTRY DATE: Entered STN: 20020619
Last Updated on STN: 20030214
Entered Medline: 20030213

L19 ANSWER 3 OF 2840 MEDLINE on STN
TI A barbourin-**albumin fusion protein** that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.
AB Barbourin is a 73 amino acid venom protein that inhibits platelet aggregation. Recombinant barbourin (BARH6), rabbit serum albumin (RSAH6), and a barbourin-RSA fusion protein (barbourin-linker-albumin; BLAH6) were secreted from Pichia pastoris yeast, and purified by nickel-chelate affinity chromatography via their C-terminal hexahistidine (H6) tags. BARH6 and BLAH6 did not differ in their IC50s for inhibition of platelet aggregation using either human platelets stimulated with thrombin or ADP, or rabbit platelets stimulated with ADP. BARH6 and BLAH6 were also effective in inhibiting platelet aggregation in whole blood, and formed complexes with platelet integrin alphaIIbbeta3. The terminal catabolic half-life of BLAH6 approached that of RSAH6 [3.4 +/- 0.2 versus 4.0 +/- 0.1 days (n = 4 +/- SD)], but was substantially increased relative to that of BARH6 [0.15 +/- 0.03 days (n = 3 +/- SD)]. Our results suggest that fusion to albumin slows the clearance of barbourin in vivo, while preserving its ability to inhibit platelet aggregation.

ACCESSION NUMBER: 2001535476 MEDLINE
DOCUMENT NUMBER: 21467016 PubMed ID: 11583325
TITLE: A barbourin-**albumin fusion protein** that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.
AUTHOR: Marques J A; George J K; Smith I J; Bhakta V; Sheffield W P
CORPORATE SOURCE: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
SOURCE: THROMBOSIS AND HAEMOSTASIS, (2001 Sep) 86 (3) 902-8.
Journal code: 7608063. ISSN: 0340-6245.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200204
ENTRY DATE: Entered STN: 20011004

Last Updated on STN: 20020409
Entered Medline: 20020408

L19 ANSWER 4 OF 2840 MEDLINE on STN
TI Prolonged in vivo anticoagulant activity of a hirudin-**albumin fusion protein** secreted from Pichia pastoris.
AB Hirudin is a small, proteinaceous thrombin inhibitor that clears rapidly from the circulation. A hexahistidine-tagged hirudin-rabbit serum albumin (RSA) fusion protein, HLAH6, was characterized following secretion from Pichia pastoris. HLAH6 bound to immobilized nickel, anti-RSA, and anti-hexahistidine antibodies, and contained the expected (ITYTD) N-terminus. Its spectrometric mass was 74,490 (versus the theoretical mass of 74,410 and sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobility of 84 kDa). The terminal catabolic half-life in rabbits of HLAH6, recombinant Pichia-derived His-tagged RSA, or plasma-derived RSA did not differ. Injection of 2 mg/kg HLAH6 into rabbits raised the activated partial thromboplastin time (aPTT) above initial values for 4-24 h, while the equimolar dose of unfused hirudin was without significant effect. A higher dose of HLAH6 (3 mg/kg functional HLAH6, equivalent to 37.6 thrombin-inhibitory units/g) raised the aPTT by 2.0- to 2.5-fold; the elevation persisted for > 48 h. Importantly, both HLAH6 and unfused hirudin inhibited clot-bound thrombin. Our results suggest that HLAH6 exhibits not only delayed clearance, but also prolonged biological activity in vivo compared with unfused hirudin.

ACCESSION NUMBER: 2001506683 MEDLINE
DOCUMENT NUMBER: 21439005 PubMed ID: 11555696
TITLE: Prolonged in vivo anticoagulant activity of a hirudin-**albumin fusion protein** secreted from Pichia pastoris.
AUTHOR: Sheffield W P; Smith I J; Syed S; Bhakta V
CORPORATE SOURCE: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ont., Canada.. sheffiel@mcmaster.ca
SOURCE: BLOOD COAGULATION AND FIBRINOLYSIS, (2001 Sep) 12 (6) 433-43.
Journal code: 9102551. ISSN: 0957-5235.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200112
ENTRY DATE: Entered STN: 20010917
Last Updated on STN: 20020122
Entered Medline: 20011204

L19 ANSWER 5 OF 2840 USPATFULL on STN
TI Tumor necrosis factor receptors 6 alpha & 6 beta
AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL
TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta
INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Feng, Ping, Germantown, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 13403

L19 ANSWER 6 OF 2840 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010134	A1	20040115	
APPLICATION INFO.:	US 2001-833245	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L19 ANSWER 7 OF 2840 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219875	A1	20031127	
APPLICATION INFO.:	US 2001-833118	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 2840 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using

these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:282700 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Ballance, David J., Berwyn, PA, UNITED STATES Sleep, Darrell, West Bridgford, UNITED KINGDOM Prior, Christopher P., Rosemont, PA, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199043	A1	20031023	
APPLICATION INFO.:	US 2001-832501	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	60			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	18 Drawing Page(s)			
LINE COUNT:	14339			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 2840 USPATFULL on STN

TI Binding polypeptides for B lymphocyte stimulator protein (BLyS)

AB Binding polypeptides comprising specific amino acid sequences are disclosed that bind B Lymphocyte Stimulator (BLyS) protein or BLyS-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting or isolating BLyS protein or BLyS-like polypeptides in solutions or mixtures, such as blood, tissue samples, or conditioned media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:276718 USPATFULL			
TITLE:	Binding polypeptides for B lymphocyte stimulator protein (BLyS)			
INVENTOR(S):	Beltzer, James P., Carlisle, MA, UNITED STATES Potter, M. Daniel, Acton, MA, UNITED STATES Potter, Marilou, Acton, MA, UNITED STATES LR Fleming, Tony J., Waltham, MA, UNITED STATES Ladner, Robert Charles, Ijamsville, MD, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003194743	A1	20031016	
APPLICATION INFO.:	US 2001-932322	A1	20010817	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-226489P		20000818	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			

LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., YANKWICH & ASSOCIATES, 201 Broadway, Cambridge, MA, 02139
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 6942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 2840 USPATFULL on STN
TI Neutrokine-alpha and neutrokine-alpha splice variant
AB The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokine-alpha and neutrokine-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on

12 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-329508P	20011017 (60)
	US 2001-329747P	20011018 (60)
	US 2001-330835P	20011031 (60)
	US 2001-331478P	20011116 (60)
	US 2001-336726P	20011207 (60)
	US 2002-368548P	20020401 (60)
	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 18884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 2840 USPATFULL on STN
TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:244853 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Prior, Christopher P., Rosemont, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-256931P		20001221 (60)
	US 2000-199384P		20000425 (60)
	US 2000-229358P		20000412 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	59		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	13208		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 2840 USPATFULL on STN

TI Death domain containing receptors

AB The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:243794 USPATFULL		
TITLE:	Death domain containing receptors		
INVENTOR(S):	Yu, Guo-Liang, Berkeley, CA, UNITED STATES Ni, Jian, Germantown, MD, UNITED STATES Gentz, Reiner L., Belo Horizonte, BRAZIL Dillon, Patrick J., Carlsbad, CA, UNITED STATES		
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc. (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170203	A1	20030911
APPLICATION INFO.:	US 2002-189189	A1	20020705 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-557908, filed		

on 21 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED, Pat. No. US 6153402

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-314314P	20010824 (60)
	US 2001-303155P	20010706 (60)
	US 1999-136741P	19990528 (60)
	US 1999-130488P	19990422 (60)
	US 1997-37341P	19970206 (60)
	US 1996-28711P	19961017 (60)
	US 1996-13285P	19960312 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 83
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 9858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 13 OF 2840 USPATFULL on STN
TI Chemokine beta-1 fusion proteins
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 15446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 14 OF 2840 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also

encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:181414 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	29			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	20 Drawing Page(s)			
LINE COUNT:	15235			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 2840 USPATFULL on STN

TI Binding polypeptides and methods based thereon

AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:133480 USPATFULL			
TITLE:	Binding polypeptides and methods based thereon			
INVENTOR(S):	Beltzer, James P., Carlisle, MA, UNITED STATES Potter, M. Daniel, UNITED STATES Potter, Marilou, Acton, MA, UNITED STATES LR Fleming, Tony J., Waltham, MA, UNITED STATES Rosen, Craig A., Laytonsville, MD, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003091565	A1	20030515	
APPLICATION INFO.:	US 2001-932613	A1	20010817	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 11834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 16 OF 2840 USPATFULL on STN
TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
AB KAL protein is identified as the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:102360 USPATFULL
TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE
Soussi-Yanticostas, Nadia, Paris, FRANCE
Hardelin, Jean-Pierre, Paris, FRANCE
Sarailh, Catherine, Marseille, FRANCE
Rougon, Genevieve, Marseille, FRANCE
Legouis, Renaud, Strasbourg, FRANCE
Ardouin, Olivier, Issy-les-Mou-lineaux, FRANCE
Mazie, Jean-Claude, Asnieres, FRANCE
PATENT ASSIGNEE(S): Institut Pasteur, Paris, FRANCE (non-U.S. corporation)
Centre National de la Recherche Scientifique, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6548475	B1	20030415
APPLICATION INFO.:	US 2000-576967		20000524 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-761136, filed on 6 Dec 1996, now patented, Pat. No. US 6121231
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ulm, John
ASSISTANT EXAMINER: Chernyshev, Olga N.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 1338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 2840 USPATFULL on STN
TI Serum albumin binding moieties
AB Compositions comprising non-naturally occurring serum albumin binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to albumin. Preferred serum albumin binding peptides having a high affinity

for human serum albumin are particularly disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:100284 USPATFULL
TITLE: Serum albumin binding moieties
INVENTOR(S): Sato, Aaron K., Somerville, MA, UNITED STATES
Ley, Arthur C., Newton, MA, UNITED STATES
Cohen, Edward H., Belmont, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069395	A1	20030410
APPLICATION INFO.:	US 2002-94401	A1	20020308 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-331352P	20010309 (60)
	US 2001-292975P	20010523 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LEON R. YANKWICH, YANKWICH & ASSOCIATES, 201 BROADWAY, CAMBRIDGE, MA, 02139
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 4384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 2840 USPATFULL on STN
TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:86793 USPATFULL
TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE
Soussi-Yanticostas, Nadia, Paris, FRANCE
Hardelin, Jean-Pierre, Paris, FRANCE
Sarailh, Catherine, Marseille, FRANCE
Rougon, Genevieve, Marseille, FRANCE
Legouis, Renaud, Strasbourg, FRANCE
Ardouin, Olivier, Issy-les-Mou-lineaux, FRANCE
Mazie, Jean-Claude, Asnieres, FRANCE
PATENT ASSIGNEE(S): INSTITUT PASTEUR, PARIS CEDEX, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060401	A1	20030327
APPLICATION INFO.:	US 2002-219541	A1	20020816 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-576967, filed on 24 May 2000, PENDING Division of Ser. No. US 1996-761136, filed on 6 Dec 1996, GRANTED, Pat. No. US 6121231
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 19 OF 2840 USPATFULL on STN
TI Tumor necrosis factor receptors 6alpha & 6beta
AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:272468 USPATFULL
TITLE: Tumor necrosis factor receptors 6alpha & 6beta
INVENTOR(S): Gentz, Reiner L., Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150583	A1	20021017
APPLICATION INFO.:	US 2001-935727	A1	20010824 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131270P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 12989
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 2840 USPATFULL on STN

TI Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury

AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:228307 USPATFULL
TITLE:	Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
INVENTOR(S):	Petit, Christine, Le Plessis-Robinson, FRANCE Soussi-Yanicostas, Nadia, Paris, FRANCE Hardelin, Jean-Pierre, Paris, FRANCE Saraiib, Catherine, Marseille, FRANCE Rougon, Genevieve, Marseille, FRANCE Legouis, Renaud, Strasbourg, FRANCE Ardouin, Olivier, Issy Les Moulineaux, FRANCE Mazie, Jean-Claude, Asnieres, FRANCE
PATENT ASSIGNEE(S):	INSTITUT PASTEUR, Paris Cedex, FRANCE, 75724 (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123467	A1	20020905
APPLICATION INFO.:	US 2002-119714	A1	20020411 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-319236, filed on 2 Sep 1999, PENDING A 371 of International Ser. No. WO 1997-EP6806, filed on 5 Dec 1997, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Page(s)		
LINE COUNT:	1904		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 21 OF 2840 USPATFULL on STN

TI Hyaluronan receptor protein

AB The present invention relates to a novel hyaluronan receptor protein involved in cell locomotion or motility and in cell proliferation and transformation and to DNA sequences encoding this protein. The protein is designated Receptor for Hyaluronic Acid Mediated Motility or RHAMM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:194945 USPATFULL
TITLE:	Hyaluronan receptor protein
INVENTOR(S):	Turley, Eva Ann, #5 - 375 Wellington Crescent, Winnipeg, Manitoba, CANADA L2M 0A1 Zhang, Shuwen, 143 Branson Crescent, Winnipeg, Manitoba, CANADA R2P 9N9 Entwistle, Jocelyn, 380 Linden Wood Drive East, Winnipeg, Manitoba, CANADA R3P 2H1

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6429291 B1 20020806
APPLICATION INFO.: US 1995-477831 19950607 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-20740	19941014

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kemmerer, Elizabeth
LEGAL REPRESENTATIVE: Fish & Neave, Pierri, Margaret A., Mayrand, Shawn-Marie
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 123 Drawing Figure(s); 70 Drawing Page(s)
LINE COUNT: 3544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 22 OF 2840 USPATFULL on STN
TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury
AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:125008 USPATFULL
TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, France
Soussi-Yanticostas, Nadia, Paris, France
Hardelin, Jean-Pierre, Paris, France
Sarailh, Catherine, Marseilles, France
Rougon, Genevieve, Marseilles, France
Legouis, Renaud, Strasbourg, France
Ardouin, Olivier, Issy-les-Mou-lineaux, France
Mazie, Jean-Claude, Asnieres, France
PATENT ASSIGNEE(S): Institut Pasteur, Paris, France (non-U.S. corporation)
Centre Nationale de la Recherche Scientifique, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121231		20000919
APPLICATION INFO.:	US 1996-761136		19961206 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Duffy, Patricia A.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 1334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68074 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68074 protein DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #4.

L19 ANSWER 24 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68075 protein DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68075 protein DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425

US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #5.

L19 ANSWER 25 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68073 protein DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.
ACCESSION NUMBER: ADD68073 protein DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #3.

L19 ANSWER 26 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68072 protein DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.
ACCESSION NUMBER: ADD68072 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #2.

L19 ANSWER 27 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68005 peptide DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence is used in the examples of the present invention.
ACCESSION NUMBER: ADD68005 peptide DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Yeast invertase (SU2) leader-hGH N-terminal fusion peptide.

L19 ANSWER 28 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68077 protein DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their

fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68077 protein DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #7.

L19 ANSWER 29 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68076 protein DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68076 protein DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #6.

L19 ANSWER 30 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
AN ADD68071 peptide DGENE
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.
ACCESSION NUMBER: ADD68071 peptide DGENE
TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.
INVENTOR: Rosen C A; Haseltine W A
PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.
PATENT INFO: US 2003125247 A1 20030703 180p
APPLICATION INFO: US 2001-833041 20010412
PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #1.